Business, energy, technology, markets and global industry news from Business News Today

Gemelli Biotech

PharmaDeviceNews Gemelli Biotech
Gemelli Biotech’s IBS-Smart and Trio-Smart testing was linked to lower use of selected diagnostic procedures and lower captured diagnostic costs in a real-world irritable bowel syndrome study. Representative image.
Medical Devices & Diagnostics

Gemelli Biotech IBS-Smart study finds lower diagnostic costs in patients with suspected IBS

Gemelli Biotech’s IBS-Smart and Trio-Smart were linked to lower captured diagnostic costs in a 219-patient IBS study, but causality remains unproven.

Read More
Representative image of gastrointestinal diagnostic research, highlighting how Gemelli Biotech’s Trio-Smart breath test and IBS-Smart blood test could support more precise IBS and SIBO assessment after DDW 2026 data presentations.
Medical Devices & Diagnostics

Why Gemelli Biotech’s 3-gas breath test could reshape how clinicians evaluate SIBO

Gut diagnostics need proof, not buzz. Gemelli Biotech’s DDW 2026 visibility could test whether IBS and SIBO care is ready for precision tools.

Read More